TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
Dollar Near Two-Week High as Stock Rout, AI Concerns and Global Events Drive Market Volatility 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
U.S. Stock Futures Edge Higher as Tech Rout Deepens on AI Concerns and Earnings 
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
South Korea’s Celltrion Inc. will jointly develop and work on the market release with Abpro Corp. of the US on a breast cancer treatment candidate ABP 10
Under the deal, Celltrion will receive US$10 million in milestone payments after successfully passing key stages of the development and approval cycle.
Celltrion, an Incheon-based biopharmaceutical company, will also be eligible to collect $1.75 billion from Abpro after ABP 102 generates sales following its market debut. Additionally, it has secured the rights for the candidate's international sales.
The Massachusetts-based Abpro is developing eight other cancer treatment candidates.
ABP 102 is a dual antibody treatment used to treat breast cancer that is HER2-positive.
